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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease associated with a complex genetic etiology.
Besides the apolipoprotein E ε4 (APOE ε4) allele, a few dozen other genetic loci associated with AD have been
identified through genome-wide association studies (GWAS) conducted mainly in individuals of European ancestry.
Recently, several GWAS performed in other ethnic groups have shown the importance of replicating studies that
identify previously established risk loci and searching for novel risk loci. APOE-stratified GWAS have yielded novel AD
risk loci that might be masked by, or be dependent on, APOE alleles. We performed whole-genome sequencing (WGS)
on DNA from blood samples of 331 AD patients and 169 elderly controls of Korean ethnicity who were APOE ε4
carriers. Based on WGS data, we designed a customized AD chip (cAD chip) for further analysis on an independent set
of 543 AD patients and 894 elderly controls of the same ethnicity, regardless of their APOE ε4 allele status. Combined
analysis of WGS and cAD chip data revealed that SNPs rs1890078 (P= 6.64E−07) and rs12594991 (P= 2.03E−07) in
SORCS1 and CHD2 genes, respectively, are novel genetic variants among APOE ε4 carriers in the Korean population. In
addition, nine possible novel variants that were rare in individuals of European ancestry but common in East Asia were
identified. This study demonstrates that APOE-stratified analysis is important for understanding the genetic
background of AD in different populations.
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia, accounting for 60–70% of all cases1. In the
United States, the prevalence of AD in people aged 65
years and older is forecast to increase from 4.7% in 2010
to 13.8% in 20502,3. Likewise, in South Korea, the
prevalence of AD in people aged 65 years and older is
forecast to increase from 9.95% in 2017 to 16.09% in
20504.
Late-Onset Alzheimer’s disease (LOAD), the non-
Mendelian form of AD, accounts for >99% of AD and is
highly heritable (estimates of 58–79%), with complex
genetic etiology5,6. The APOE ε4 allele is the strongest
genetic risk factor for LOAD, with a population attribu-
table fraction of approximately 30–35%7. The search for
additional genetic risk factors through genome-wide
association studies (GWAS) conducted mainly in Eur-
opean populations have yielded a few dozen genetic loci,
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beyond APOE ε4, associated with LOAD8–12. However,
the genetic liability of AD by APOE and GWAS findings is
estimated to be only 24–33%, which is not enough to
explain the 58–79% heritability for AD revealed by twin
studies5,6.
The effects of many risk loci differ across ethnic groups.
For example, variants in ABCA7 have greater effects on
AD risk for individuals of African–American ancestry
than on those of European ancestry13. One main reason
for this is differences in frequencies of risk alleles in dif-
ferent ethnic groups, which affects calculations of odds
ratios and statistical significance. Many AD loci can be
revealed by focusing on ethnic groups other than Eur-
opean. For example, GWAS in non-European populations
have identified novel genetic risk factors associated with
AD, such as SORL1 from Japanese studies and ACE from
Israeli–Arabs14,15. Morris et al. recently showed that racial
differences are correlated with molecular biomarkers,
such as the levels of t-tau and p-tau181 proteins in cere-
brospinal fluid of AD patients16. Several GWAS where
individuals were stratified based on APOE status have also
led to the identification of novel loci17,18. For example,
KANSL1 region on chromosome 17 near MAPT was
identified using only APOE ε4 negative (APOE ε4-) sam-
ples in the International Genomics of Alzheimer’s Project
(IGAP)17. Novel associations were also identified with
variants in ISYNA1, OR8G5, IGHV3-7, and SLC24A3,
among APOE ε4 carriers19. We therefore rationalized that
we would be more likely to find novel genetic variants by
focusing on a subgroup of individuals of Korean ethnicity
that was stratified based on APOE ε4 allele status.
The goal of the present study was to identify genetic
markers that are significantly associated with AD among
APOE ε4 carriers in the Korean population by conducting
the following analyses: (1) identifying possible candidate
markers from a dataset of 500 whole-genome sequencing
(WGS) comprised of 331 AD cases and 169 controls; (2)
designing a customized genotyping AD chip (cAD chip)
containing our WGS candidates and previously known
genetic variants associated with AD; and (3) validating
significant genetic markers in independent datasets from
the Korean population by using the cAD chip.
Materials and methods
Sample information
In total, 331 AD patients and 169 control participants
aged 70 years or older, with normal cognitive ability, were
recruited as a discovery set. All 500 participants used in
the discovery set were of Korean descent and bore the
APOE ε4 positive (APOE ε4+) allele. A separate set of
1915 participants, also of Korean descent, including 287
bearing the APOE ε4+ allele, were recruited as a valida-
tion set. All participants were enrolled on the basis of the
medical records written by Geriatric neuropsychiatrists
with expertise in dementia research. Each participant’s
cognitive status was diagnosed based on a medical history
assessment, neuropsychological test, and medical imaging
with magnetic resonance imaging or amyloid positron
emission tomography data. All study protocols were
reviewed and approved by the relevant Institutional
Review Boards at the Samsung Medical Center, Seoul,
South Korea.
Whole-genome sequencing analysis
WGS data were generated using the Illumina HiSeq X
Ten platform (Illumina, San Diego, CA, USA). Library
construction and 150-bp paired-end sequencing were
performed according to the manufacturer’s instructions.
The average depth showed 18× coverage of the whole
genome. Sequencing fastq data were aligned to the
reference genome, hg19, with the decoy sequence using
the BWA-mem algorithm implemented in BWA 0.7.1020.
Duplicate reads were removed using Picard 1.1 (https://
broadinstitute.github.io/picard/). Variant detection was
performed using GenomeAnalysisTK-3.3–021. Variant
annotation was conducted using ANNOVAR22 for
refGene with dbSNP 147; population frequency was
assessed with gnomAD23. In total, 22,526,987 variants
(SNPs and indels) were obtained from the raw variant call
set. We applied the following hard filter criteria: (1)
exclude multi-allelic variants; (2) include variants with
total read depth over six; (3) include variants with alter-
native read depth over three, (4) exclude segmental
duplication variants, and (5) exclude very rare variants
with minor allele frequency (MAF) less than 0.1%.
Design of the customized genotyping AD chip
To validate our candidates, we designed a cAD chip
(based on an Axiom® myDesign GW genotyping array;
Thermo Fisher Scientific, Waltham, MA, USA) that would
allow precise genetic characterization of samples in the
context of genetic variants associated with AD. Candi-
dates available on the cAD chip were taken from three
primary sources: variants in AD-related databases, var-
iants reported in the literature, and candidates from the
WGS analysis of the discovery set.
For known AD-related candidates, we referenced the
AlzGene database (http://www.alzgene.org/), the NHGRI-
EBI GWAS catalog (www.ebi.ac.uk/gwas/), the single
nucleotide polymorphism database (dbSNP; https://www.
ncbi.nlm.nih.gov/SNP/), the Human Gene Mutation
Database (HGMD; http://www.hgmd.cf.ac.uk/), as well as
other candidates reported in the literature. From the
AlzGene database, we selected 1448 genetic variants
associated with AD24. A systematic review of published
literature was performed to include variants known to be
involved in AD. We used the NHGRI-EBI GWAS catalog
curated from published GWAS since 200825. The GWAS
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catalog data were downloaded from the University of
California, Santa Cruz table browser, and candidates were
selected that included the word “Alzheimer” for disease
and trait type. The AD chip also contains the IGAP data
released from the 2013 meta-analysis results for AD8. We
selected 4131 variants with P values less than 0.00001 in
the stage 1 results of 17,008 AD cases and 37,154 controls.
Meta-analysis results included an independent set of 8572
AD cases and 11,312 controls with combined P values.
We also considered APOE-stratified GWAS results re-
analyzed from IGAP consortium data for APOE ε4+
(10,352 cases and 9207 controls) and APOE ε4- (7184
cases and 26,968 controls) subgroups. An additional 1127
candidates were derived from the original article pub-
lished by Jun et al.17. Exonic variants located in APP,
PSEN1, and PSEN2, known to cause autosomal dominant
early-onset AD, were included from dbSNP 147 and
HGMD (Supplementary Table 1).
To prioritize variants from WGS analysis of the dis-
covery set, we gathered five types of candidate groups:
coding variants, non-coding variants, case-only, control-
only, and expression quantitative trait loci (eQTL) groups.
Supplementary Table 1 shows the summarized informa-
tion of the candidate variants in the cAD chip. First, to
identify association signals from coding and non-coding
region candidates, we conducted an association analysis of
whole-genome variants by comparing AD samples versus
controls for 500 WGS samples. We selected candidates
with P values less than 0.05 for variants within a coding
region and less than 0.001 for variants within a non-
coding region. This led to the inclusion of 1396 coding
variants and 29,606 non-coding variants on the chip.
Second, to include rare variants, we selected variants that
appeared in the above two samples in AD cases or con-
trols. We identified 2357 AD case-only variants and 327
control-only variants. Finally, we added 570 known eQTL
variants expressed in brain tissues from the HaploReg v4.1
database that mapped to the non-coding variants from the
500 WGS data26.
Chip genotyping and QCs
We genotyped samples from 1915 participants using the
cAD chip for replication of WGS analysis and perfor-
mance evaluation of the customized chip. All DNA
samples were extracted from whole blood. Our genotype
calling workflow on the Affymetrix® GeneTitan® plat-
form with the Axiom® myDesign GW genotyping array
was performed according to the Axiom® 2.0 reagent kit
protocol for 384 samples (Affymetrix®/Thermo Fisher
Scientific). Fifty samples previously used for WGS analysis
were also included to evaluate the cAD chip performance
in order to compare the WGS results for the corre-
sponding SNPs that overlapped both datasets. One sample
with experimental error was excluded from the
genotyping analysis. Raw CEL data files generated by the
GeneTitan® were imported into the Axiom® Analysis
Suite Software (version 3.0, Affymetrix/Thermo Fisher
Scientific), and analysis was performed using Affymetrix
Best Practices Workflow with the default threshold set-
tings. All five plates passed plate QC; 19 samples with
failing dish QC < 0.82, 70 samples with calling QC call
rates < 0.97, and five samples determined to be technical
duplicates were excluded from the analysis. The average
call rate for the passing samples was 99.57%. We also
reviewed the individual clinical charts for each patient and
adopted only AD patients and candidates with normal
cognition as controls, excluding 255 samples from parti-
cipants with mild cognitive impairment and samples from
candidates less than 55 years old. We excluded 78 samples
with discordant clinical information regarding APOE
status and sex and computed results based on the cAD
chip. After genotyping, we also applied high-accuracy
variant QC that excluded missing genotype rates > 5%,
significant deviations from Hardy–Weinberg equilibrium
P < 0.000001 in controls, and monomorphic variants, and
included the best-recommended variants from the
Axiom® Analysis Suite Software. In total, 26,242 variants
in 1437 samples, 543 AD cases, and 894 healthy controls
including 190 AD cases and 97 controls from the APOE
ε4 carriers, were used for the final analysis.
Statistical analysis
All statistical analyses, including association analysis,
were performed using PLINK version 1.0927 and the sta-
tistical software R (R Foundation for Statistical Comput-
ing, Austria). LocusZoom software was used to depict
candidate regions in detail28. Linkage disequilibrium (LD)
information from the 1000 Genomes Project (1KGP) and
functional annotation of non-coding variants were
obtained from HaploReg v4.126.
Results
Identification of candidate variants by using WGS in a
Korean population
We conducted WGS of AD patients and matched
controls in a Korean population who were APOE ε4 car-
riers, to find genetic variants dependent on APOE ε4 allele
status, which is highly associated with AD pathogenesis.
Our WGS analysis identified 22,526,987 variants from an
APOE ε4 carrier dataset comprised of 331 AD patients
and 169 controls. Results from all the samples confirmed
that there was an ethnic overlap in genetic background
with the East Asian population (JPT+CHB population)
and that there was no population stratification in our
discovery set (Supplementary Fig. 1). To overcome lim-
itations in sample size and lack of power to reach
genome-wide significance, we replicated 34,256 variants
identified by WGS using a cAD chip (Supplementary
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Table 1). The chip included known variants associated
with AD collected from various sources such as the IGAP.
Clinical and demographic characteristics are shown in
Supplementary Table 2. Our discovery and validation
procedures are schematized in Fig. 1.
Characterization of cAD chip content and concordance
with WGS
In total, the AD chip contains 41,735 autosomal variants
and 745 X-chromosome variants. Of these, 40,395 (95.1%)
variants were found in the single nucleotide polymorph-
ism database (dbSNP) build 147. In addition, 2113 small
insertion or deletion variants were also included in the
cAD chip. Annotation using ANNOVAR showed that the
cAD chip contained 4855 exonic, 14,155 intronic, and
20,416 intergenic variants (Supplementary Tables 3 and 4).
To evaluate the accuracy of the cAD chip, we compared
50 samples randomly selected from the WGS discovery
set. All samples exhibited high call rates (average=
99.59%) and dish quality control (QC) (average= 0.97) in
the results generated by the cAD chip analysis. The
average concordance rate of 25,416 autosomal genotype
calls that overlapped both the cAD chip and WGS gen-
otypes in 50 samples was 99.29% (range= 98.47–99.69%).
Considering SNPs exclusively, we observed high con-
cordance rates ranging from 98.50% to 99.70% (average=
99.31%).
Known genetic variants associated with AD in cAD chip
application set
We first examined the reproducibility of previously
reported AD loci in 543 AD cases and 894 controls in the
cAD chip application set (Table 1). We assessed
40 susceptibility loci previously reported to be associated
with AD from four GWAS published by Andrews et. al.11.
We identified 12 loci: CR1, BIN1, CD2AP, GPR141,
PILRA, EPHA1, CLU, PICALM, SORL1, SLC24A2,
ABCA7, and APOE, exhibiting significant association (P
value < 0.05) in the cAD chip analysis. The APOE region
in particular [best SNP: rs429358, P= 2.59 × 10-33, OR=
4.81 (95% CI: 3.76–6.16)] exhibited the highest significant
association signal in the Korean population. APOE ε4 is
the strongest genetic risk factor for AD, that has been
identified in recent decades. The PICALM region [best
SNP: rs3851179, P= 2.25 × 10−3, OR= 0.78 (95% CI:
0.67–0.92)] was also replicated in our data and showed an
effect size similar to that observed in the IGAP study
(Fig. 2). Our best SNP (rs3851179) in the PICALM region
is in high LD (r2= 1 based on the 1KGP phase 1 popu-
lation) with the SNP previously reported as the best level
of association (rs10792832) with AD in IGAP results8.
Although the EPHA1 region showed a significant asso-
ciation [best SNP: rs11771145, P= 4.75 × 10−3, OR= 1.24
(95% CI: 1.06–1.44)], the allelic effect of the same SNP
from a previous report was in the opposite direction [OR:
1.24 (95% CI: 1.06–1.44) vs. 0.90 (95% CI: 0.88–0.93)].
Our study corroborated the association of known AD
variants reported by Lambert et al. in a Korean popula-
tion8. BIN1 [rs6733839, P= 0.049, OR= 1.17 (95% CI:
1.00–1.36)], CLU [rs9331896, P= 0.021, OR= 0.81(95%
CI: 0.68–0.97)], PICALM [rs10792832, P= 0.0029, OR=
0.79(95% CI: 0.67–0.92)], and ABCA7 [rs4147929, P=
0.045, OR= 1.18 (95% CI: 1.01–1.38)] showed significant
association with the same risk allele and direction in cAD
chip results. However, we observed that not all SNPs
showing the best level of association in the IGAP study
Discovery set (APOE ε4 carriers)
Whole genome sequencing (WGS)
Korean patients with AD (n=331) vs Control (n=169)
cAD Chip application set
Korean patients with AD (n=543) vs Control (n=894)
A
Replication set (APOE ε4 carriers)
Application of Customized AD Chip
Korean patients with AD (n=190) vs Control (n=97)
Combined analysis (APOE ε4 carriers)
Replicated 2 novel variants (SORCS1 and CHD2)
Korean patients with AD (n=521) vs Control (n=266)
P < 0.000001 in the 
combined set 
(APOE ε4 carriers)




WGS data from the discovery set
9,275 variants
Known variants from IGAP 
(P < 0.00001) and literature review
34,256 variants
Known loci with P < 0.05 Suggestive nine novel variants with P < 0.005
P < 0.05 in 
known loci P < 0.005
Fig. 1 Schematic workflows. The schematic workflow shows the procedures for detecting novel genetic variants associated with Alzheimer’s
Disease (AD) in a Korean population of APOE ε4 carriers (A) and for assessing the reproducibility of previously reported AD loci and suggestive novel
loci shown to be population-specific (B). cAD customized genotyping AD chip, IGAP International Genomics of Alzheimer’s Project.
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Plotted SNPs
Fig. 2 Regional plot of known loci (11q14.2; PICALM and 19q13.32; APOE) that are significantly associated with Alzheimer’s disease (AD) in
the cAD chip application set. The figures show the regional association plot of known representative loci, (A) 11q14.2; PICALM and (B) 19q13.32;
APOE, in the cAD chip application set (n= 1,437). The purple shaded diamond shape represents rs3851179 and rs429358, which are the most
significant SNPs in 11q14.2 (A) and 19q13.32 (B), respectively. The blue line indicates the recombination rate, while filled color represents the linkage
disequilibrium score based on r2 values estimated from the 1000 genome Nov 2014 ASN data.
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were not the most strongly associated SNPs in the loci
analyzed in our dataset. One such example is rs4732729
[P= 0.013, OR= 0.80 (95% CI: 0.67–0.96)], located in
CLU, which exhibits a more significant association than
rs9331896. Notably, the allelic effect (minor allele) of
rs4732729 was opposite to that of the IGAP dataset [OR:
0.80 (95% CI: 0.67–0.96) vs. OR: 1.12 (95% CI:
1.07–1.16)]. This discrepancy may be attributed to the
different LD relationships between rs9331896 and
rs4732729 (r2= 0.96 based on 1KGP phase 1 ASN
population and r2= 0.33 based on the 1KGP phase 1 EUR
population) in different population. This suggests that it is
important to interpret the results while considering the
population LD structure. Ethnic comparison of known
variants reported from IGAP between Korean and Eur-
opean populations showed a low correlation coefficient
(r= 0.216, P < 2.2E−16; Supplementary Fig. 2). Taken
together, our results suggest that there are ethnic differ-
ences in associated SNPs at loci related to AD among
populations, even when shared risk variants are associated
with AD.
Novel variants associated with AD in APOE ε4 carriers
We identified two novel AD-associated SNPs in APOE
ε4 carriers with a discovery P value < 10−3, a replication P
value of 0.05, and a combined P value < 10−6 (Table 2).
One intergenic SNP between SORCS1 and LINC01435
[rs1890078; P= 6.64 × 10−7, OR= 0.43 (95% CI:
0.30–0.61)] showed higher MAF allele, C in control
samples as a protective effect associated with reduced risk
of AD (Fig. 3). Located in the intron of CHD2, SNP
rs12594991, showed higher frequency of the minor allele,
A in AD cases. The frequency of the A allele in
rs12594991 in the European population (0.52) is much
higher than in the Asian population (0.15). Two SNPs
(rs1890078 and rs12594991) did not exhibit any sig-
nificant association with AD in the APOE ε4 non-carriers
(Supplementary Table 5).
Novel variants associated with AD in the cAD chip
application set
Candidate novel variants in the cAD chip application set
were selected based on the following criteria: (1) only P
values less than 0.005 were accepted; (2) MAF < 1% were
excluded; and (3) common variants in non-Finnish Eur-
opean populations with a MAF value above 0.05 from the
GnomAD database (http://gnomad.broadinstitute.org/)
were removed; and (4) only the variants with the same
direction of allelic effect, estimated using the odds ratio
between the discovery set and validation set, were
accepted. Subsequently, we identified nine AD-associated
SNPs in eight genes (CLIC4, PTPRN2, PSD3, SORCS1,
LOC102724301, LINC01578, ABR, and USP32) (Table 3).
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Fig. 3 Regional plot of novel candidate variants significantly associated within APOE ε4 carriers. The figures show the regional association
plot of known representative loci, (A) 10q25.1; SORCS1 and (B) 15q26.1; CHD2, in the cAD chip application set with a combined P value < 0.000001.
The purple shaded diamond shape represents rs1890078 and rs12594991, which are the most significant SNPs in 10q25.1 (A) and 15q26.1 (B),
respectively. The blue line indicates the recombination rate, while filled color represents the linkage disequilibrium score based on r2 values estimated
from the 1000 genome Nov 2014 ASN data.
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consortium data because they were either not genotyped
or were filtered out because of low MAF in European
populations. Significant associations were not observed
for the other three SNPs (rs12063304, rs967326, and
rs79919241) in IGAP data. Notably, two intergenic SNPs
found between SORCS1 and LINC01435 [rs144835823;
P= 8.40 × 10−4, OR= 0.32 (95% CI: 0.15–0.65) and
rs78442236; P= 9.57 × 10−5, OR= 0.17 (95% CI:
0.06–0.47)] and one intronic SNP in USP32 [rs117665140;
P= 8.17 × 10−4, OR= 1.62 (95% CI: 1.23–2.13)] were not
found in European populations but were identified in our
study. Taken together, we identified ethnic differences in
associated single nucleotide polymorphisms (SNPs) at loci
related to AD among different populations. We also
identified 15 rare LOF variants such as frameshift, stop-
gain, and stop-loss from the case-only or control-only
categories of WGS analysis. However, none of these var-
iants was significant in the cAD chip analysis.
rs1890078, previously observed in APOE ε4 carriers, was
a common variant in SORCS1. However, rs144835823 and
rs78442236 were very rare variants located approximately
24 kb and 55 kb away from the common variant, respec-
tively. In the cAD chip application set, rs1890078 showed
significant association in the APOE ε4 carriers but not in
the APOE ε4- samples, whereas association of
rs144835823 and rs78442236 with AD pathogenesis was
observed, regardless of the APOE ε4 status. rs79919241,
located in an intron of LINC01578, was approximately
82 kb away from rs12594991 in CHD2. The two variants
were in low LD (r2= 0.39) with each other, and were
identified in APOE ε4 carriers (Table 2). rs12594991 (P=
2.03 × 10−7) exhibited a significantly higher association
with APOE ε4 carriers than rs79919241 (P= 1.08 × 10−4).
These results show the importance of performing APOE
ε4 stratification analysis in case-control studies to enable
the detection of significant variants related to the APOE
ε4 allele in universal GWAS.
Discussion
Large-scale GWAS such as the IGAP have reported
various variants associated with AD; however, these stu-
dies have mainly focused on non-Asian populations, and
the genetic architecture of AD is less clear in Asian
populations. However, small-scale studies on the genetic
diversity in AD across various ethnic groups have sug-
gested the importance of understanding the genetic
background of AD in diverse populations29. Since no
large-scale genetic study of AD has been conducted in
Koreans to date, this study sought to identify genetic
variants associated with AD in a Korean population by
using a large sample size. We discovered and validated
genetic candidates associated with AD by using WGS data
and a cAD chip dataset. Our findings provide an impor-
tant perspective on AD pathogenesis related to the APOE
ε4+ allele. The APOE ε4 allele, a well-known stratifying
risk factor for AD, has been considered to primarily elu-
cidate the genetic effects associated with AD pathogen-
esis. We suggest that a WGS approach is imperative to
maximize the detection probability of the existence of
population-specific or rare variants.
We detected two novel variants associated with AD in
the APOE ε4 stratified analysis. Chromodomain helicase
DNA binding protein 2 (CHD2) is characterized by the
presence of a chromodomain that is responsible for
chromatin remodeling. CHD2 is a risk factor for photo-
sensitivity in epilepsy30 and is related to neurodevelop-
mental disorders31–33. CHD2 has previously been
reported to interact with repressor element 1-silencing
transcription factor (REST), which plays an important role
in cognitive decline associated with AD34. The minor
allele (A) confers risk for AD, affecting the gene expres-
sion of CHD2 as cis-eQTL. According to the eQTL
database35, one novel SNP (rs12594991) with minor allele
(A) showing an association signal in the APOE ε4 carriers
was significantly associated with high expression of the
assigned gene (CHD2; FDR P < 0.001). The minor allele A
on rs12594991 might be associated with high expression
levels and increased susceptibility to AD. CHD2 protein
expression is high in the cerebral cortex and cerebellum,
that is, in brain regions rather than other organs36 (The
Human Protein Atlas; www.proteinatlas.org). Since
sortilin-related VPS10 domain-containing receptor 1
(SORCS1) is associated with sortilin, SORCS1 may be
involved in amyloid precursor protein (APP) processing
and trafficking across membranes, as is the sortilin-related
receptor (SORL1) gene, which is associated with AD
susceptibility37. Intronic genetic variations rs10884402
and rs950809 of SORCS1 associated with late-onset AD
have been reported in the Chinese Han population38.
Interestingly, the intronic variants rs12571141,
rs17277986, and rs6584777 of SORCS1 only exhibited
significant association in the APOE ε4 carriers39. How-
ever, the rs17277986 variants included in our cAD chip
did not show significant associations in our dataset. Our
novel variants in SORCS1 are located in intergenic regions
and show lower allelic frequencies than those of pre-
viously reported intronic variants. These results indicate
that functional variants with biological implications are
not always consistent with one another, despite being
localized in the same gene, SORCS1.
We also identified putative novel variants that were not
detected in European populations due to low allele fre-
quency. Although our putative novel variants were
selected by WGS analysis in the discovery stage with the
APOE ε4 carriers, they were replicated in our cAD chip
application set which was not stratified based on the
APOE ε4 genotype. When we considered the APOE ε4
carriers in our cAD chip application set, four of these
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novel variants also showed significant association (P <
0.05) (Table 3). It is not known whether the four genes
(PTPRN2, SORCS1, LINC01578, and ABR) containing the
putative novel variants in the cAD chip dataset are
directly involved in the pathogenesis of AD.
PH and SEC7 domain-containing protein 3 (PSD3)
includes the putative Pleckstrin domain, indicating that
PSD3 is involved in intracellular signaling. PSD3 was
included in 30 top-scoring SNPs identified by a Bayesian
combinatorial method in an AD GWAS dataset that was
shown to be differentially overexpressed in AD40.
Receptor-type tyrosine-protein phosphatase N2
(PTPRN2) could be involved in amyloid processing, based
on the fact that PTPRN2 is one of the substrates involved
in beta-site APP-cleaving enzyme 141. The expression of
PTPRN2 was significantly altered in the hippocampus of
AD sufferers42. The active BCR-related gene (ABR),
localized at the synapses of neurons, may be involved in
synaptic signaling; the ABR gene is abundantly expressed
in the brain43.
A number of limitations should be considered when
interpreting our results. First, although we have con-
ducted our association study with AD data from the lar-
gest Korean population size to date, it may still be
inadequate. Therefore, novel variants identified in this
study should be analyzed in a greater number of samples
to achieve genome-wide significance. Second, the rare
putative novel variants with low allele frequencies might
not be replicated in European populations. We must
validate these variants in other independent Asian
populations.
In summary, our results highlight that novel germline
variants associated with AD in APOE ε4 carriers sampled
from a Korean population were identified using whole-
genome sequencing and cAD chip genotyping. Our
results suggest that genetic association studies must be
performed in diverse ethnic populations.
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